

NCC and BCI Conduct Oncology Training Program in Ghana

Raleigh, North Carolina – October 28, 2010. The National Cancer Coalition (NCC) and the Ghana based organization Breast Care International (BCI) are pleased to announce the successful implementation of their oncology training program for registered nurses in Ghana. The program was officially sponsored by the US headquartered Johnson & Johnson and focuses on early detection of breast and cervical cancers for improved survival outcomes.

Ghanaian Vice President John Dramani Mahama met with BCI's Dr. Beatrice Wiafe Addai and NCC's Senior Vice President Tom Roane to discuss the oncology training program, as well as the coalition's medicine donations to Ghana which have exceeded \$20 million since NCC and BCI signed an official Memorandum of Understanding in July 2009, with the goal to increase Ghana's access to modern specialty medicines and healthcare technologies. The Vice President lauded the efforts of NCC and BCI in helping to develop real solutions to the meet the country's healthcare needs.

The three day training entitled "Oncology Training for Registered Nurses in Ghana" was recently hosted at Breast Cancer International's headquarters in Kumasi. The seminars were attended by RNs who work throughout Ghana, a developing country of 24 million people, where oncology training has not been a reality for most of its nurses.

NCC President Robert Landry stated, "National Cancer Coalition is pleased that our program with Breast Care International is leading to greater cancer resources for Ghana. We thank Johnson & Johnson for its support of this important training program, which complements the NCC medicine access programs through which NCC and BCI assist underserved Ghanaian patients."

Breast Care International, is a non-governmental organization dedicated to educating women about early detection of cancer and access to breast cancer care throughout Ghana, by providing the country's women with: screening examinations, diagnosis, counseling, treatment, rehabilitation, and research. Since 2002, thousands of women have been screened for breast cancer through these initiatives.

The National Cancer Coalition, a 501(c)(3) not-for-profit corporation, supports relief and research programs throughout the world. The Coalition's international medical assistance program provides requested specialty pharmaceuticals, essential medicines, hospital supplies and medical equipment to medical facilities that treat underserved patients in over 50 developing countries around the world. For additional information, please contact NCC at: 919-821-2182 or visit our website at: www.nationalcancercoalition.org

NCC and Pfizer Partner to Provide 10 Million Units of Hemophilia Medicines

Raleigh, NC, February 23, 2010. The National Cancer Coalition (NCC) is pleased to announce its recent collaboration with Pfizer, Inc to provide hemophilia medicines to underserved patients in the developing world. To date, NCC has received more than 10 million international units of ReFacto[®] Antihemophilic Factor (Recombinant), a therapy used for the treatment and prevention of bleeding in people with hemophilia A, to assist patients who otherwise would have little opportunity for adequate treatment. The value of this donation is more than \$13 million, and it will help many hundreds of hemophilia patients around the world.

“Pfizer is dedicated to developing and delivering innovative hemophilia therapies and we are proud of our partnership with the National Cancer Coalition, which is helping to distribute Pfizer-donated factor product to patients in the global hemophilia community,” says Jean-Michel Halfon, President and General Manager, Emerging Markets, Pfizer. “We are committed to working with partner organizations like NCC to provide access to hemophilia medicines to patients who need them most.”

Pfizer’s donation will help to bring much-needed hemophilia therapy to patients who may be untreated or inadequately treated. In addition, these donations help to support the development of the infrastructure which creates long term value beyond the donation itself. This current donation to the National Cancer Coalition is part of the largest hemophilia donation that has ever been made in Pfizer’s history.

“Our organization is dedicated to providing the resources and tools needed in the treatment and prevention of cancer, hemophilia, and other serious diseases and illnesses throughout the world,” says Robert Landry, President of the National Cancer Coalition. “Product donations such as Pfizer’s are essential to addressing the needs of the patients and families that we serve globally.” National Cancer Coalition, a non-governmental organization (NGO), is a preferred partner of Pfizer and the two organizations have collaborative projects in a number of other areas including cancer, depression, and arthritis.

Hemophilia A is a rare, inherited blood-clotting disorder characterized by spontaneous hemorrhages or prolonged bleeding, typically into joints and soft tissue. People with hemophilia A are deficient in a key protein — factor VIII — that is vital in the clotting mechanism to prevent bleeding. Most patients with hemophilia A are dependent on factor VIII replacement therapy.

The National Cancer Coalition, a 501(c)(3) not-for-profit corporation, supports cancer relief, research, and educational programs throughout the world. The Coalition’s international medical assistance program, termed *NCC Cares*, has provided requested specialty pharmaceuticals, essential medicines, hospital supplies and medical equipment to public hospitals and local humanitarian organizations that help needy patients in over 50 developing countries around the world. The *NCC Provides* program awards financial assistance for American cancer patients who would otherwise not be able to complete their treatments. For additional information, please contact NCC at: 919-821-2182 or visit our website at: www.nationalcancercoalition.org

Hospira Foundation Awards \$25,000 Grant To The National Cancer Coalition

By [PR Newswire](#) 05/24/10 - 06:45 AM EDT

RALEIGH, N.C., May 24 /PRNewswire-USNewswire/ -- The National Cancer Coalition (NCC) is pleased to announce that it recently received a \$25,000 grant award from the Hospira Foundation, the philanthropic arm of Hospira, Inc., to support its pharmaceutical relief program within the Dominican Republic. NCC is seeking to significantly increase the levels of medical resources that it provides to the public hospitals of the Dominican Republic in an effort to more fully treat the country's underserved patients, and this grant will contribute toward achieving that goal.

"Hospira is dedicated to advancing wellness, and the National Cancer Coalition's medical relief programs provide access to much-needed medicines and technologies for patients who would otherwise go without. We are especially proud to assist communities in which our employees work and live, and we have a strong, dedicated workforce in the Dominican Republic," said Stacey T. Eisen, vice president, Global Public Affairs, and vice president, Hospira Foundation.

Robert B. Landry, III, President of NCC commented, "The National Cancer Coalition is thrilled to receive this financial support from the Hospira Foundation." He added, "We are especially pleased with our working relationship with Hospira, a global manufacturer of specialty injectable pharmaceuticals and medical products, over the past few years and the impact realized for underserved patients with cancer and other life-threatening diseases." NCC, a non-governmental organization (NGO), has provided the Dominican Republic with requested medicines valued at over \$100 million during the past 10 years.

Hospira's donations of the colorectal cancer medicine irinotecan HCI have allowed NCC to provide access to this important drug to public hospitals that assist the underserved in the developing world. The benefiting public hospitals that have received this cancer medicine were located in: Ghana, Tanzania, Moldova, the Dominican Republic, El Salvador, Guatemala, Honduras, Jamaica, Nicaragua, Panama, Paraguay, and the Philippines. These donations have provided hundreds of poor cancer patients access to this vital chemotherapy.

The National Cancer Coalition, a 501(c)(3) not-for-profit corporation, supports relief and research programs throughout the world. The Coalition's international medical relief program provides requested pharmaceuticals to medical facilities that treat underserved patients in over 50 developing countries around the world. The *NCC Provides* program awards financial assistance for American cancer patients who would otherwise not be able to complete their treatments. For additional information, please contact NCC at: 919-821-2182 or visit our website at: www.nationalcancercoalition.org

SOURCE National Cancer Coalition

By [Business Wire](#) 02/01/10 - 02:51 PM EST

Aetna Awards \$20,000 Grant to the National Cancer Coalition

Funding will help improve the health and wellness of communities in the Dominican Republic, Ghana and the Philippines

HARTFORD, Conn., February 01, 2010 — Aetna (NYSE: [AET](#)) recently awarded a \$20,000 grant to the National Cancer Coalition (NCC), a nonprofit organization whose mission is to reduce the suffering of cancer patients and their families by providing medical and financial relief, research, and educational programs throughout the world in an effort to improve patients' quality of life.

The grant will support the NCC Cares program, which supplies hospitals and clinics in impoverished areas of Africa, Asia, Eastern Europe, and Latin America with the tools and resources needed to assist medical professionals and facilities in the treatment and prevention of cancer and other serious diseases. The program provides chemotherapies, chronic and essential medicines, laboratory and diagnostic equipment, and much needed medical supplies to benefit underserved patients in some of the poorest areas in the world.

“The donation to NCC compliments Aetna’s position on being proactive about preventing, educating and treating illnesses, such as cancer,” says Tim Blevins, Head of Medical and Network Operations for Aetna Global Benefits. “It also highlights our company’s commitment to international health and wellness issues.”

Aetna Global Benefits (AGB), the international business segment of Aetna, recently implemented Phase III of its Aetna Global Health Connections program, of which cancer education and support is a new component of its International Disease Management Program.

Robert B. Landry, President of NCC, stated, “National Cancer Coalition is honored to receive this support for our humanitarian programs from Aetna. The NCC Cares program is the world’s largest cancer-focused medical relief program and this award from Aetna will allow us to provide assistance to countless additional patients with cancer and other life-threatening diseases.”

About Aetna

Aetna is one of the nation’s leading diversified health care benefits companies, serving approximately 36.3 million people with information and resources to help them make better informed decisions about their health care. Aetna offers a broad range of traditional and consumer-directed health insurance products and related services, including medical, pharmacy, dental, behavioral health, group life and disability plans, and medical management capabilities and health care management services for Medicaid plans. Our customers include employer groups, individuals, college students, part-time and hourly workers, health plans, governmental units, government-sponsored plans, labor groups and expatriates. For more information, see www.aetna.com.

National Cancer Coalition Announces Angel Grant Recipients

Raleigh, NC – July 30, 2009. The National Cancer Coalition (NCC) is pleased to announce its recent *Angel Grant* recipients, which include: Dr. Steven Brem of the H. Lee Moffitt Cancer Center, Dr. Julie Blatt of the University of North Carolina - Chapel Hill, Dr. Jeffrey Taub of the Children's Hospital of Michigan, and Dr. Eric Beyer of the University of Chicago.

Steven S. Brem, M.D., is the Director of Neurosurgery and the Division Chief of the Neuro-Oncology Department at H. Lee Moffitt Cancer Center in Tampa. Dr. Brem is utilizing his *Angel Grant* to pursue the development of new anti-angiogenic therapies for pediatric brain tumors.

Julie Blatt, M.D., is the Chief of Pediatric Hematology/Oncology at the University of North Carolina at Chapel Hill. Her award furthered UNC's study demonstrating no overall link between autism and cancer in children, as well as a teaching program for childhood cancer survivors and healthcare providers.

Jeffrey W. Taub, M.D., is the Director of the Hematology/Oncology Fellowship Program at the Children's Hospital of Michigan. Dr. Taub's grant will be used to provide a new visible wavelength microplate reader, which is integral to his innovative research and treatment of acute leukemias.

Eric C. Beyer, M.D., Ph.D., is the Chief of Pediatric Hematology/Oncology at the University of Chicago's Comer Children's Hospital. His *Angel Grant* will be used to further his investigations of the biology of pediatric Glioblastoma multiforme (GBM) brain tumors and their treatment.

The National Cancer Coalition implemented its *Angel Grant* program to provide seed funding to innovative projects that benefit and further cancer research, education, and programs. Grants are also awarded to act as a catalyst for scientists to secure additional funding from United States government agencies and other sources. For more information on *Angel Grants* and how to apply, please visit our website at: www.nationalcancercoalition.org.

The National Cancer Coalition, a 501(c)(3) not-for-profit corporation, supports cancer relief, research, and educational programs throughout the world. The Coalition's international medical assistance program, termed *NCC Cares*, provides requested pharmaceuticals, medical equipment, and hospital supplies to public hospitals and local humanitarian organizations that help needy patients in over 40 developing countries around the world. The *NCC Provides* program awards financial assistance for American cancer patients who would otherwise not be able to complete their treatments. For additional information, please contact NCC at: 919-821-2182 or visit our website at: www.nationalcancercoalition.org.

NCC and Wyeth Donation to Assist Cancer Patients in Latin America

LIMA, Peru, Jan. 14 /PRNewswire/ -- The National Cancer Coalition (NCC) and Wyeth Pharmaceuticals (Wyeth) are pleased to announce a pilot program to assist cancer patients in Latin America with donations of Wyeth's cancer-related medicines Mylotarg(TM) (gemtuzumab ozogamicin for injection) and Neumega(TM) (oprelvekin).

United States Ambassador Michael McKinley and the Peruvian Health Ministry participated in a hand-over event held at the Instituto Nacional de Enfermadades Neoplacias (INEN) in Lima, along with representatives from National Cancer Coalition, Wyeth Pharmaceuticals, INEN, and the Peruvian media. This donation to INEN, which is the largest public cancer hospital in Peru, consists of life-saving medicines valued at over \$500,000.

Ambassador McKinley stated, "The event we are celebrating today is very important for several reasons. First, because this donation is the light of hope for many cancer patients in Peru who, due to the large quantity of medicines being donated today, will have access to life-saving treatment. In addition, this event is very special because it underscores the importance of public-private partnerships and the concrete gains that can be achieved with these partnerships to meet the critical health care needs of our citizens."

Eduardo Nieto, President, Wyeth Pharmaceuticals, Latin America, commented, "Wyeth is dedicated to aiding patients in need, and we are honored to be partnering with NCC in this initiative to provide oncology medicines to underserved patients in Peru."

"National Cancer Coalition is pleased that this new program with Wyeth Pharmaceuticals will lead to greater oncology resources for patients in the developing world. Through this donation, it is anticipated that over 100 Peruvian leukemia patients will be helped at INEN this year. NCC looks forward to expanding our medicine donation initiatives with Wyeth, as we jointly seek to help patients who would otherwise lack access to their required specialty medicines," stated Robert B. Landry, President of NCC. In the last five years, NCC has provided over \$9 million worth of donated cancer medicines to INEN hospitals.

National Cancer Coalition, a 501(c)(3) not-for-profit corporation, supports cancer relief, research and educational programs throughout the world. The Coalition's international medical assistance program, termed *NCC Cares*, provides requested pharmaceuticals, medical equipment, and hospital supplies to public hospitals and local humanitarian organizations that help needy patients in over 40 developing countries around the world.

For additional information, please contact National Cancer Coalition at: 919-821-2182 or visit our website at <http://www.nationalcancercoalition.org>.